Epoch Investment Partners Inc. Grows Stock Position in Bristol Myers Squibb Company $BMY

Epoch Investment Partners Inc. increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 4.7% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,228,074 shares of the biopharmaceutical company’s stock after acquiring an additional 55,319 shares during the period. Epoch Investment Partners Inc. owned approximately 0.06% of Bristol Myers Squibb worth $74,483,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Bayban purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at about $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on BMY. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Finally, Bank of America decreased their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $61.25.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
• Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
• Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
• Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
• Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

Bristol Myers Squibb Stock Up 0.9%

Shares of BMY opened at $62.05 on Friday. The company’s 50-day simple moving average is $57.49 and its 200-day simple moving average is $58.03. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The stock has a market capitalization of $126.70 billion, a PE ratio of 17.43, a P/E/G ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the previous year, the business posted $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.